Blog | HemaCare

HemaCare Bone Marrow Tissue Boosts Development of Cell Therapy for Sickle Cell Disease

Dec 12, 2018 10:10:00 AM / by Nancy Andon, MSc posted in bone marrow-derived stem cells, bone marrow, sickle cell disease

0 Comments

An independent study cites the use of HemaCare-sourced human bone marrow-derived CD34+ stem cells for research into a potential new therapy for sickle cell disease. [1]

Sickle cell is a serious disease that affects millions of people throughout the world. People affected by sickle cell anemia have rigid, sickle-shaped red blood cells that can’t adequately carry oxygen to the body’s tissues. As a result, sickle cell patients suffer from a variety of medical complications, which can shorten their life span. Contemporary cell therapy treatments have focused on a gene therapy approach that uses lentiviral vectors to supply CD34+ bone marrow-derived stem cells with an unimpaired version of the hemoglobin gene. While this tactic has met with some promise, finding healthy, matched bone marrow donors is difficult. Researchers at Biogen, a well-known biotech firm headquartered in Cambridge, Massachusetts, are trying to discover cell and gene therapy methods that they hope will provide an alternative solution, and thereby improve treatment success rates.

Read More

The Role of CD34+ Stem Cells in Treating Cardiovascular Disease

Mar 20, 2017 2:49:36 PM / by Stacy Matthews Branch, DVM, PhD posted in Bone marrow, bone marrow, Cardiovascular Disease, CD34, cell therapy, stem cell research, stem cell therapy, Stem Cell Therapy, stem cells

0 Comments

The leading cause of death for U.S. citizens is cardiovascular disease, which affects nearly a third of the U.S. population. There is an active and dedicated search for effective therapies to address this serious medical issue. The use of immunotherapy approaches for a number of diseases and conditions is continuously gaining momentum. Included in this is the use of CD34+ stem cells from a patients’ own blood (autologously derived) to treat cardiovascular disease. CD34+ is derived from bone marrow and other tissue types. However, CD34+ stems cells are more widely known for their hematopoietic origin.

Read More

Stroke Patient Walks Again After Experimental Stem Cell Therapy

Jan 18, 2017 12:00:18 AM / by Stacy Matthews Branch, DVM, PhD posted in Bone marrow, bone marrow, cell therapy, stem cell research, stem cell therapy, Stem Cell Therapy, stem cell transplantation, stem cells

0 Comments

Nearly 7 million people in the U.S. (about 2% of the total U.S. population) suffer some level of stroke-related brain damage and related health problems. Studies in animals suggest that cell-based therapies can improve post-stroke outcomes. To determine the safety of cell-therapy approaches in humans, researchers from Stanford University conducted a clinical trial to study the safety of a procedure to transplant donor stem cells in the brains of patients with chronic stroke. 

Read More

A New Method to Enrich for Osteoprogenitors in Stem Cells

Jun 27, 2016 1:00:23 PM / by Dalia Gaddis posted in Bone, Bone marrow, bone marrow, CD34, osteoprogenitors, Stem Cell Therapy, stem cells, tissue regeneration

0 Comments

Scientists find that the marker CD34 may enrich for osteoprogenitors in bone marrow stem cells.

The use of stem cells for bone regeneration is an idea that scientists have been experimenting with for a few decades. In a previous blog, we highlighted new research where stem cells isolated from extracellular vesicles can help regenerate bone tissue. Here, we focus on another exciting study that may benefit bone regeneration from these cells.

Read More

Microglia, a Product of Bone Marrow Stem Cells, Tie up Loose Ends of Ruptured Blood Vessels

Jun 13, 2016 1:00:50 PM / by Steffen Porwollik posted in blood vessel, Bone marrow, bone marrow, bone marrow-derived stem cells, hemorrhagic stroke, macrophages, research, vascular repair

0 Comments

Scientists discover and visualize the astonishing capability of microglia, macrophages circulating in the brain, to repair broken blood vessels. This finding may open up new avenues for treatment of hemorrhagic strokes and brain microbleeds associated with dementia and cognitive decline.

Every four minutes, a person dies from a stroke in the US. A staggering 15 million people worldwide suffer from an occurrence of this disease every year. Strokes are thus incredibly common and extremely serious. The majority of these strokes is caused by a disruption of the blood flow to the brain, and therapy approaches using pluripotent stem cells show much promise. However, about 13% of strokes are hemorrhagic in nature, where brain blood vessels rupture and blood flows freely into the brain tissue.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts